Dr. Benjamin A. Teply, MD

Dr. Teply practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Teply's NPI, 1770803645, was assigned on June 2, 2010. Dr. Teply graduated from University of Nebraska College of Medicine in 2010. Dr. Teply holds Nebraska license 29950.

Dr. Teply's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Teply also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Teply's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Teply is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Teply to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Teply practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Teply's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Teply's licenses on file in 2 states: Nebraska and Michigan.

CMS data shows 564 Medicare services from Dr. Teply across 7 procedure codes in 2024, for 191 Medicare patients. Medicare paid $34,683 for them.

CMS counts 191 Medicare patients who saw Dr. Teply in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Teply's median patient age at 74, with 10% women.

In 2024, Dr. Teply wrote 711 Medicare Part D claims for 91 patients. 59% of them were for generic drugs. CMS names the drug for 557 of them, across 15 drugs with 11 or more claims each, at $3,494,741 in total drug cost. In 2023, CMS named 616 claims across 18 drugs.

Dr. Teply accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Teply as offering telehealth.

Dmand AI links 43 papers to Dr. Teply, published from 2012 to 2025. 2021 was the busiest year, with 7. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Androgen Antagonists. Dr. Teply has published most often in Expert Rev Clin Pharmacol. Dr. Teply's most frequent co-authors are Samuel Ray Denmeade, MD, Surinder K. Batra, MD and Michael Anthony Carducci, MD.

Dmand AI links Dr. Teply to 6 clinical trials, 2 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Transitional Cell, Carcinoma, Renal Cell and Lymphatic Metastasis. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 20 general payments to Dr. Teply from 8 drug and device companies from 2019 to 2024. Consulting fees make up the largest share, 74% of the total. Eli Lilly and Company paid the most, $6,400.

Dr. Teply graduated from University of Nebraska College of Medicine in 2010.